|
Shenzhen Weiguang Biological Products Co., Ltd. (002880.sz) Valoración de DCF
CN | Healthcare | Drug Manufacturers - Specialty & Generic | SHZ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ) Bundle
¡Descubra el verdadero potencial de Shenzhen Weiguang Biological Products Co., Ltd. (002880SZ) con nuestra calculadora DCF avanzada! Ajuste los supuestos clave, explore varios escenarios y evalúe los efectos de los cambios en la valoración de Shenzhen Weiguang, todo dentro de una sola plantilla de Excel.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 821.5 | 904.6 | 907.4 | 667.9 | 1,048.5 | 1,156.0 | 1,274.6 | 1,405.3 | 1,549.4 | 1,708.2 |
| Revenue Growth, % | 0 | 10.12 | 0.31728 | -26.39 | 56.98 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 |
| EBITDA | 238.6 | 266.7 | 301.5 | 207.2 | 350.2 | 361.1 | 398.1 | 438.9 | 483.9 | 533.6 |
| EBITDA, % | 29.05 | 29.48 | 33.22 | 31.02 | 33.4 | 31.24 | 31.24 | 31.24 | 31.24 | 31.24 |
| Depreciation | 39.8 | 46.5 | 57.2 | 66.8 | 89.4 | 80.5 | 88.8 | 97.9 | 107.9 | 119.0 |
| Depreciation, % | 4.84 | 5.14 | 6.31 | 10.01 | 8.53 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 |
| EBIT | 198.8 | 220.2 | 244.2 | 140.3 | 260.8 | 280.6 | 309.3 | 341.1 | 376.0 | 414.6 |
| EBIT, % | 24.21 | 24.35 | 26.91 | 21.01 | 24.87 | 24.27 | 24.27 | 24.27 | 24.27 | 24.27 |
| Total Cash | 304.6 | 471.5 | 332.1 | 294.6 | 252.3 | 448.5 | 494.4 | 545.1 | 601.0 | 662.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 232.8 | 246.7 | 204.3 | 208.5 | 141.1 | 283.9 | 313.0 | 345.1 | 380.5 | 419.5 |
| Account Receivables, % | 28.33 | 27.27 | 22.51 | 31.21 | 13.46 | 24.56 | 24.56 | 24.56 | 24.56 | 24.56 |
| Inventories | 467.7 | 383.9 | 421.7 | 605.5 | 673.0 | 695.2 | 766.5 | 845.1 | 931.7 | 1,027.3 |
| Inventories, % | 56.94 | 42.44 | 46.47 | 90.65 | 64.19 | 60.14 | 60.14 | 60.14 | 60.14 | 60.14 |
| Accounts Payable | 20.0 | 24.1 | 29.0 | 33.1 | 77.5 | 47.7 | 52.6 | 58.0 | 64.0 | 70.5 |
| Accounts Payable, % | 2.43 | 2.66 | 3.19 | 4.96 | 7.4 | 4.13 | 4.13 | 4.13 | 4.13 | 4.13 |
| Capital Expenditure | -77.8 | -189.2 | -240.8 | -327.4 | -328.9 | -317.4 | -350.0 | -385.9 | -425.5 | -469.1 |
| Capital Expenditure, % | -9.47 | -20.92 | -26.54 | -49.01 | -31.36 | -27.46 | -27.46 | -27.46 | -27.46 | -27.46 |
| Tax Rate, % | 10.92 | 10.92 | 10.92 | 10.92 | 10.92 | 10.92 | 10.92 | 10.92 | 10.92 | 10.92 |
| EBITAT | 171.8 | 191.4 | 208.0 | 120.1 | 232.3 | 243.1 | 268.0 | 295.5 | 325.8 | 359.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -546.7 | 122.7 | 34.0 | -324.3 | 37.2 | -188.6 | -88.7 | -97.8 | -107.9 | -118.9 |
| WACC, % | 5.2 | 5.2 | 5.19 | 5.19 | 5.21 | 5.2 | 5.2 | 5.2 | 5.2 | 5.2 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -523.9 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | -124 | |||||||||
| Terminal Value | -10,321 | |||||||||
| Present Terminal Value | -8,011 | |||||||||
| Enterprise Value | -8,535 | |||||||||
| Net Debt | 247 | |||||||||
| Equity Value | -8,782 | |||||||||
| Diluted Shares Outstanding, MM | 227 | |||||||||
| Equity Value Per Share | -38.72 |
Benefits You Will Receive
- Pre-Loaded Financial Model: Utilize Shenzhen Weiguang Biological Products Co., Ltd.'s (002880SZ) actual performance data for accurate DCF valuation.
- Comprehensive Forecasting Control: Modify revenue projections, profit margins, WACC, and other essential parameters as needed.
- Real-Time Calculations: Automatically updated results allow immediate insights as adjustments are made.
- Professional-Grade Template: A polished Excel file specifically designed for high-quality valuation purposes.
- Flexible and Reusable: Customizable layout to facilitate ongoing use for in-depth financial forecasts.
Key Features
- Comprehensive 002880SZ Data: Pre-loaded with the historical financial information and future projections for Shenzhen Weiguang Biological Products Co., Ltd.
- Highly Customizable Settings: Tailor inputs such as revenue growth rates, profit margins, WACC, tax percentages, and capital expenditures.
- Interactive Valuation Model: Automatically refreshes Net Present Value (NPV) and intrinsic value based on your personalized inputs.
- Scenario Analysis: Generate various forecasting scenarios to evaluate different outcome valuations.
- Intuitive Interface: A clean and organized design, suitable for both professionals and novice users.
How It Functions
- Download the Template: Gain instant access to the Excel-based [Symbol] DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and additional parameters.
- Instant Calculations: The model automatically computes Shenzhen Weiguang Biological Products Co., Ltd.'s intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the results to inform your investment or financial analysis decisions.
Why Choose This Calculator for Shenzhen Weiguang Biological Products Co., Ltd. (002880SZ)?
- User-Friendly Interface: Perfectly tailored for both novices and seasoned professionals.
- Customizable Inputs: Easily adjust parameters to suit your specific analysis.
- Immediate Feedback: Observe real-time updates to the valuation of Shenzhen Weiguang as you modify inputs.
- Preloaded Data: Comes with actual financial information from Shenzhen Weiguang for swift evaluations.
- Relied Upon by Experts: A preferred tool for investors and analysts seeking actionable insights.
Who Can Benefit from This Product?
- Investors: Effectively assess the fair value of Shenzhen Weiguang Biological Products Co., Ltd. (002880SZ) prior to making investment choices.
- CFOs: Utilize a top-tier DCF model for detailed financial analysis and reporting.
- Consultants: Easily customize the template for client valuation reports.
- Entrepreneurs: Discover insights into the financial modeling practices of leading biotech firms.
- Educators: Employ it as a resource to illustrate various valuation techniques.
Contents of the Template
- Pre-Filled DCF Model: Financial data for Shenzhen Weiguang Biological Products Co., Ltd. (002880SZ) preloaded for immediate utilization.
- WACC Calculator: Comprehensive calculations for the Weighted Average Cost of Capital.
- Financial Ratios: Assess Shenzhen Weiguang Biological Products Co., Ltd. (002880SZ)'s profitability, leverage, and operational efficiency.
- Editable Inputs: Modify assumptions such as growth rates, profit margins, and capital expenditures to align with your scenarios.
- Financial Statements: Access annual and quarterly reports for thorough analysis.
- Interactive Dashboard: Effortlessly visualize key valuation metrics and outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.